HOME >> MEDICINE >> NEWS
Emselex(R) receives positive CHMP opinion for the treatment of overactive bladder

Basel, 30th July 2004 Novartis Pharma AG announced today that the Committee for Medicinal Products for Human Use (CHMP), adopted a positive opinion recommending that the European Commission (EC) grant a Marketing Authorisation for Emselex (darifenacin hydrobromide), 7.5mg and 15mg, for the treatment of overactive bladder (OAB) in all 25 European Union (EU) countries as well as Norway and Iceland. Upon receipt of the EC approval, Novartis will be able to market Emselex throughout these countries.

"We are delighted by the CHMP's positive opinion for Emselex, to provide overactive bladder sufferers with a new safe and effective treatment option", said Jrg Reinhardt, Global Head of Development Novartis Pharma AG. "Due to its M3 selectivity, Emselex provides effective overactive bladder symptom relief while decreasing the potential risk of safety issues such as cognitive impairment or effects on cardiac function."

OAB affects almost one in six adults in Europe1. Symptoms of overactive bladder are urinary urgency (a sudden compelling desire to pass urine, which is difficult to defer) with or without urge incontinence (involuntary leakage accompanied by urgency), urinary frequency (voiding the bladder too often), and nocturia (waking at night one or more times to void the bladder).

The CHMP based its positive opinion on Emselex's comprehensive data package for OAB. The safety and efficacy of Emselex has been extensively studied in over 90 pre-clinical studies and clinical trials, involving more than 5,000 patients. Pivotal studies explored key endpoints including the reduction in the number of incontinence episodes per week, the reduction in the number of voluntary urination episodes (micturition) per day, the reduction in the episodes and severity of urgency and an increase in the average volume of urine passed per micturition.

The phase III clinical
'"/>


30-Jul-2004


Page: 1 2 3

Related medicine news :

1. UIC professor receives international humanitarian award
2. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
3. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
4. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
5. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
6. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
7. American Academy of Neurology program receives Grassroots Award
8. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
9. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
10. Pfizers antifungal medicine VFEND receives FDA approval
11. Shire receives US FDA approval of EQUETRO (TM) for bipolar disorder

Post Your Comments:
(Date:7/30/2015)... ... July 30, 2015 , ... Case Mason ... services for consumer brands, recently completed a consolidation of all of its production ... company operated out of two separate locations situated 11 miles apart. , The ...
(Date:7/29/2015)... ... July 30, 2015 , ... Macro Wealth Management (MWM) Presidents have ... a Lifetime program by encouraging their clients to donate their MWM planning fees to ... Mart McClellan and Tim Streid, who see charitable giving as an important part of ...
(Date:7/29/2015)... Washington D.C. (PRWEB) , ... July 29, 2015 , ... ... 2016 average monthly Medicare Part D premium is expected to remain stable at $32.50, ... said. , “The popular Part D program continues to be a bright spot in ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... organizations that seek to help with the problems of substance abuse that face ... Against Drunk Driving (MADD) to come to their rehabilitation center. The facility, located ...
(Date:7/29/2015)... ... July 29, 2015 , ... The power of social ... that give small businesses financial support, social connections can be used to accomplish ... health management programs, unveiled today a downloadable resource for employers that provides guidance ...
Breaking Medicine News(10 mins):Health News:Case Mason Consolidates Operations to Larger Facility for Increased Efficiency, Improved Service 2Health News:Case Mason Consolidates Operations to Larger Facility for Increased Efficiency, Improved Service 3Health News:Smile for a Lifetime (S4L) Partners with Macro Wealth Management (MWM) Helping More Children Get Braces 2Health News:MADD Victim Services Specialist Visits A Forever Recovery Rehabilitation Facility 2Health News:StayWell Unveils Employer Guide to Developing Effective Employee Wellness Champion Networks 2Health News:StayWell Unveils Employer Guide to Developing Effective Employee Wellness Champion Networks 3Health News:StayWell Unveils Employer Guide to Developing Effective Employee Wellness Champion Networks 4
(Date:7/29/2015)... July 29, 2015  Unilife Corporation ("Unilife" or the ... developer, manufacturer and supplier of injectable drug delivery systems, ... that provides the Company with flexibility and control to ... has signed an equity purchase agreement for up to ... a Chicago -based institutional investor, which ...
(Date:7/29/2015)... July 29, 2015  Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet medical ... call on July 30, 2015, at 9:00 a.m. Eastern ... 2 pediatric study of once-weekly TransCon Growth Hormone. The ... results before the market opens on July 30, 2015. ...
(Date:7/29/2015)... 2015 Varian Medical Systems, Inc., (NYSE: VAR ... European subsidiaries, agreed to acquire Claymount, a privately-held, ... for X-ray imaging equipment manufacturers. Varian,s subsidiary in ... in cash for Claymount. The transaction is expected to ... one of the world,s leading suppliers of high voltage ...
Breaking Medicine Technology:Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4Unilife Announces Multifaceted Financing Strategy 5Ascendis Pharma A/S to Report Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone and Host Conference Call on Thursday, July 30, 2015 at 9:00 a.m. Eastern Time 2Varian Medical Systems Acquiring Claymount to Expand Imaging Components Portfolio 2Varian Medical Systems Acquiring Claymount to Expand Imaging Components Portfolio 3Varian Medical Systems Acquiring Claymount to Expand Imaging Components Portfolio 4
Cached News: